

team, and descriptive and inferential statistical analyses were performed with SPSS, version 25. Statistical significance was set at the 5% level.

**Results:** The definition of constipation was defined as receiving any laxative agent during the study period, and the point prevalence rate of constipation in the chronic schizophrenic inpatients was 74.7%. Three factors were found relevant with constipation with statistical significance. The combined use of first-generation and second-generation antipsychotic medications (OR=3.28 95% CI:1.14-9.46) was regarded as detrimental factors while both increased education years (OR=0.92, 95% CI: 0.87-0.97) and more exercises (more attendance to the twice-a-day self-initiated aerobic exercises) (OR=0.47, 95% CI: 0.23-0.97) were found protective.

**Conclusions:** The point prevalence rate of constipation was much higher than other similar studies locally or internationally, but, however, such result also faithfully revealed the fact that constipation is literally a ubiquitous health problem among the chronic schizophrenic inpatients. The researchers suggested that performing health education on constipation, enhancing the extent of aerobic exercises and promoting health behaviours for positive cycle, and discussing with the prescribing physicians to simplify the use of antipsychotic agents may mitigate the risk of constipation.

**Disclosure of Interest:** None Declared

## EPV1836

### A first case association of Lambert-Eaton Myasthenic Syndrome and First Episode Psychosis: a case report

C. Siopa<sup>1\*</sup>, C. Cordeiro<sup>1</sup> and B. M. Moura<sup>2,3</sup>

<sup>1</sup>Department of Neurosciences and Mental Health, ULS Santa Maria, Lisbon, Portugal; <sup>2</sup>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, Netherlands and <sup>3</sup>Católica Medical School, Catholic University of Portugal, Lisbon, Portugal

\*Corresponding author.

doi: 10.1192/j.eurpsy.2025.2266

**Introduction:** Lambert-Eaton Myasthenic Syndrome is an autoimmune neuromuscular junction disorder characterized by proximal weakness, autonomic dysfunction, and areflexia associated with antibodies against voltage-gated calcium channels. Psychotic symptoms can take place in many auto-immune neurological disorders, but their occurrence in myasthenic syndromes has rarely been observed.

**Objectives:** We report a case of a 21-year-old female with primary autoimmune Lambert-Eaton Myasthenic Syndrome due to anti-voltage-gated calcium channels antibodies subtype P/Q, who developed psychotic symptoms three years after motor symptom onset. **Methods:** The patient attended regular psychiatric follow-ups over three years.

**Results:** With monthly administration, these psychotic symptoms improved after every cycle of intravenous immunoglobulin therapy. The patient displayed partial insight into the mental symptoms. Different causes of reversible psychosis were excluded, such as autoimmune encephalitis and paraneoplastic syndrome, though the patient tested positive for the anti-voltage-gated calcium channels antibodies subtype P/Q. Owing to muscle strength worsening and psychotic episodes, the patient was put on several treatments,

including one admission to a Neurology unit. The patient then experienced psychotic exacerbation, leading to treatment with olanzapine at 20 mg/day. Psychotic symptoms persisted but were less severe, with greater intensity at night. After two years, the patient's condition showed significant improvement, with olanzapine increased to 25 mg/day.

**Conclusions:** This is, to our knowledge, the first described case of psychotic symptoms associated with Lambert-Eaton Myasthenic Syndrome. We speculate that voltage-gated calcium channel antibodies could have a role in developing mental symptoms. However, further hypotheses are discussed. Although the patient had received corticosteroid therapy before symptom onset, the timing and dosage make corticosteroid-induced psychosis unlikely. A primary psychotic disorder, such as schizophrenia, is considered improbable due to the atypical nature of the psychotic symptoms. This case underscores the need for further research on the neurobiological mechanisms linking VGCC antibodies to psychiatric symptoms.

**Disclosure of Interest:** None Declared

## EPV1837

### Cognitive Functions in Schizophrenic Patients: A Case-Control Tunisian Study

N. Smaoui<sup>1</sup>, D. Jarak<sup>1\*</sup>, R. feki<sup>1</sup>, S. Omri<sup>1</sup>, I. Gassara<sup>1</sup>, M. Bou Ali Maalej<sup>1</sup>, N. Charfi<sup>1</sup>, J. Ben Thabet<sup>1</sup>, M. Maalej<sup>1</sup>, L. Zouari<sup>1</sup> and L. Triki<sup>2</sup>

<sup>1</sup>psychiatry C, Hedi Chaker University Hospital and <sup>2</sup>Functional Explorations, Habib Bourguiba University Hospital SFAX, Sfax, Tunisia

\*Corresponding author.

doi: 10.1192/j.eurpsy.2025.2267

**Introduction:** Cognitive impairments in schizophrenic patients are present from the first psychotic episode and remain relatively stable over time. These cognitive impairments primarily affect memory, attention, executive functions, and social cognition.

**Objectives:** The aim of this study was to assess cognitive functions in schizophrenic patients by comparing them to healthy controls.

**Methods:** Methods: We conducted a cross-sectional, descriptive, and analytical case-control study. It included 15 schizophrenic patients and 15 healthy controls. The study was carried out at the Psychiatry « c » Department outpatient unit at Hedi Chaker University Hospital in Sfax, Tunisia. Both cases and controls underwent interviews to answer predefined questionnaires. We used the Screen For Cognitive Impairment in Psychiatry (SCIP) scale in its literary Arabic version for the assessment of cognitive functions.

**Results:** The average scores for the total SCIP (ST) and its five subscales (Verbal Learning Test-Immediate (VLT-I), working memory (WMT), verbal fluency (VFT), verbal learning-Test-delayed (VLT-D), and processing speed Test (PST)) were 37.40, 12.87, 14.27, 3.93, 2.47, and 3.93, respectively, for the cases, and 47.27, 15, 18.13, 5.40, 4.33, and 4.40, respectively, for the controls. The cases had significantly lower total SCIP scores than the controls ( $p=0.05$ ), specifically in the WMT ( $p=0.02$ ) and VLT-D ( $p=0.01$ ) subscales. There was no significant difference between the two groups in the VLT-I ( $p=0.241$ ), VFT ( $p=0.202$ ), and PST ( $p=0.598$ ) subscales.

**Conclusions:** This study found that cognitive deficits in schizophrenic patients primarily involved impairments in working